BioAdvance

Tolerance Bio is a biopharmaceutical company dedicated to extending healthspan by restoring and preserving the function of the thymus, a critical organ for immune system regulation. The company's innovative approach involves creating artificial, bio-engineered thymus tissue using induced pluripotent stem cells (iPSCs), which can then be used to establish and maintain immune tolerance in patients, potentially treating a wide range of immune-mediated diseases.

ViTToria Biotherapeutics is a company focused on developing gene-edited cell therapies, specifically next-generation T-cell therapeutics that aim to address significant unmet medical needs. Utilizing its proprietary Senza5 Technology, ViTToria enhances the efficacy, safety, and overall utility of cell-based treatments in preclinical settings. The company's innovative approach seeks to lower dosing requirements, simplify preconditioning regimens, reduce manufacturing failures, and shorten vein-to-vein times. This technology enables medical practitioners to improve patient outcomes, positioning ViTToria Biotherapeutics as a pioneer in the advancement of cell therapy solutions.

KayoThera is a biotechnology company focused on developing innovative therapeutics aimed at treating late-stage and metastatic cancers. Founded in 2019 and based in Princeton, New Jersey, the company specializes in creating first-in-class immuno- and targeted therapies. Its primary approach involves inhibiting a key enzyme that protects cancer cells and depleting regulatory T-cells, which enhances the effectiveness of existing chemotherapy and immunotherapy treatments. KayoThera's mission is to provide new hope for patients facing previously incurable cancers by advancing its therapeutic programs.

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Wayne, Pennsylvania, established in 2015. The company specializes in developing and commercializing targeted therapies for serious and rare genetic skin diseases, focusing on addressing the root causes of these conditions. Its lead product candidate, QTORIN, is an anhydrous gel formulated to ensure drug stability at room temperature while enabling effective distribution into skin layers where various dermatologic pathologies occur. Palvella Therapeutics is committed to serving patient populations that have been overlooked, with an initial emphasis on conditions such as microcystic lymphatic malformations and cutaneous venous malformations, leveraging its patented QTORIN platform to advance its therapeutic pipeline.

Senzo Health is a company focused on developing innovative in vitro diagnostics technology aimed at enhancing the accessibility and accuracy of medical testing. The company has created a portable blood diagnostic platform that allows for the simultaneous execution of common laboratory tests. By leveraging novel technologies, Senzo Health offers mobile, point-of-care, and self-testing products that enable individuals to conduct tests quickly and cost-effectively. This approach empowers people to take control of their healthcare information, ultimately improving their quality of life.

Innervace is a regenerative therapy company established in 2018 and based in Philadelphia, Pennsylvania. It focuses on developing and commercializing implantable tissue-engineered brain pathways aimed at addressing neurodegenerative disorders. The company's primary innovation is its tissue-engineered nigrostriatal pathway, which is designed to replicate the lost nigrostriatal pathway in patients suffering from Parkinson's disease. This advanced technology offers a solution that reconstructs brain pathways rather than merely alleviating symptoms temporarily, thus providing a more effective treatment option for individuals with such conditions.

Senzo Health is a company focused on developing innovative in vitro diagnostics technology aimed at enhancing the accessibility and accuracy of medical testing. The company has created a portable blood diagnostic platform that allows for the simultaneous execution of common laboratory tests. By leveraging novel technologies, Senzo Health offers mobile, point-of-care, and self-testing products that enable individuals to conduct tests quickly and cost-effectively. This approach empowers people to take control of their healthcare information, ultimately improving their quality of life.

Halo Labs is a life science instrumentation company based in Burlingame, California, specializing in the development of tools for biologics researchers. Formerly known as Optofluidics, the company focuses on high throughput biopharmaceutical quality control, utilizing advanced optics, image processing, and microfluidics technologies. Halo Labs' offerings include assessment of biologics-developability, formulation development, late-stage formulation, small molecule solubility, and AAV analytics. Founded in 2011, the company has gained recognition for its innovative scientific platform, which provides critical insights into the particles involved in research processes, thereby enhancing the stability and quality assessment of biological drugs.

KayoThera is a biotechnology company focused on developing innovative therapeutics aimed at treating late-stage and metastatic cancers. Founded in 2019 and based in Princeton, New Jersey, the company specializes in creating first-in-class immuno- and targeted therapies. Its primary approach involves inhibiting a key enzyme that protects cancer cells and depleting regulatory T-cells, which enhances the effectiveness of existing chemotherapy and immunotherapy treatments. KayoThera's mission is to provide new hope for patients facing previously incurable cancers by advancing its therapeutic programs.

Phrase Health, Inc. is a Philadelphia-based company founded in 2018 that specializes in software solutions for the healthcare sector. The company has developed a workflow management platform that enables hospitals to monitor and analyze the information provided to doctors and nurses at the point of care. This platform assists healthcare professionals in managing decisions and examining user interactions, allowing them to identify actionable insights. Phrase Health's tools facilitate data-driven process improvements and help coordinate strategic initiatives within healthcare settings, ultimately enhancing the quality of care delivered to patients.

Wellsheet is a technology company that specializes in optimizing clinical information management through the use of machine learning and artificial intelligence. Its cloud-based platform integrates seamlessly with existing Electronic Health Record (EHR) systems, enabling healthcare providers to access prioritized and contextualized clinical content tailored to their workflows. By enhancing the visibility of the most relevant information, Wellsheet empowers physicians to make quicker clinical decisions, thus improving patient care and operational efficiency. The company's solutions have demonstrated significant benefits in large health systems, including a notable impact within a network of 10,000 physicians in New Jersey. Additionally, Wellsheet collaborates with major EHR vendors like Epic and Cerner to distribute its services, operating on a Software as a Service (SaaS) model for healthcare organizations.

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Wayne, Pennsylvania, established in 2015. The company specializes in developing and commercializing targeted therapies for serious and rare genetic skin diseases, focusing on addressing the root causes of these conditions. Its lead product candidate, QTORIN, is an anhydrous gel formulated to ensure drug stability at room temperature while enabling effective distribution into skin layers where various dermatologic pathologies occur. Palvella Therapeutics is committed to serving patient populations that have been overlooked, with an initial emphasis on conditions such as microcystic lymphatic malformations and cutaneous venous malformations, leveraging its patented QTORIN platform to advance its therapeutic pipeline.

Halo Labs is a life science instrumentation company based in Burlingame, California, specializing in the development of tools for biologics researchers. Formerly known as Optofluidics, the company focuses on high throughput biopharmaceutical quality control, utilizing advanced optics, image processing, and microfluidics technologies. Halo Labs' offerings include assessment of biologics-developability, formulation development, late-stage formulation, small molecule solubility, and AAV analytics. Founded in 2011, the company has gained recognition for its innovative scientific platform, which provides critical insights into the particles involved in research processes, thereby enhancing the stability and quality assessment of biological drugs.

Ride Health LLC is a healthcare technology company that provides a software-as-a-service platform designed to facilitate patient transportation to medical appointments. Founded in 2016 and headquartered in New York, the company collaborates with healthcare organizations and transportation providers to streamline the management of transportation benefits. Its platform allows healthcare coordinators to schedule rides for patients in advance or on-demand, while also offering real-time insights into transportation costs and usage. By integrating technology with a human-centered approach, Ride Health addresses transportation barriers faced by at-risk populations, ensuring that patients receive the necessary care. The platform personalizes the ride experience by mapping out each patient's unique needs, ultimately leading to improved access to care, greater efficiencies, reduced costs, and better health outcomes.

Renovacor, Inc., established in 2013 and headquartered in Philadelphia, Pennsylvania, is a biopharmaceutical company dedicated to developing transformative gene therapies for cardiovascular diseases. Currently in the preclinical stage, Renovacor's primary focus is on creating a recombinant adeno-associated virus (AAV)-based gene therapy targeting patients with dilated cardiomyopathy (DCM) caused by mutations in the Bcl2-associated athanogene 3 (BAG3) gene. This condition affects approximately 35,000 individuals in the United States and Europe, qualifying it as an orphan disease. Renovacor aims to improve patient outcomes by potentially preventing disease progression through a BAG3 gene replacement therapy, given the current five-year survival rate of only 50% for DCM patients despite standard care.

Pillo Health is a company focused on enhancing the quality of life for patients managing their health at home through its innovative care delivery platform. Central to this platform is Pillo, an intelligent healthcare assistant designed to assist caregivers and health organizations in delivering improved care. Pillo manages medication schedules, provides personalized health and wellness information, and proactively delivers digital care plans to patients. Additionally, it facilitates communication between patients and care teams through smart notifications and video calling. Pillo Health also offers a software development kit (SDK) that allows partner organizations to create customized skills for the Pillo device, further expanding its capabilities in home healthcare management.

Phrase Health, Inc. is a Philadelphia-based company founded in 2018 that specializes in software solutions for the healthcare sector. The company has developed a workflow management platform that enables hospitals to monitor and analyze the information provided to doctors and nurses at the point of care. This platform assists healthcare professionals in managing decisions and examining user interactions, allowing them to identify actionable insights. Phrase Health's tools facilitate data-driven process improvements and help coordinate strategic initiatives within healthcare settings, ultimately enhancing the quality of care delivered to patients.

Halo Labs is a life science instrumentation company based in Burlingame, California, specializing in the development of tools for biologics researchers. Formerly known as Optofluidics, the company focuses on high throughput biopharmaceutical quality control, utilizing advanced optics, image processing, and microfluidics technologies. Halo Labs' offerings include assessment of biologics-developability, formulation development, late-stage formulation, small molecule solubility, and AAV analytics. Founded in 2011, the company has gained recognition for its innovative scientific platform, which provides critical insights into the particles involved in research processes, thereby enhancing the stability and quality assessment of biological drugs.

ENB Therapeutics, Inc. is a biopharmaceutical company based in New York, New York, that specializes in developing small molecule inhibitors aimed at treating melanoma and other cancers. Founded in 2015, the company focuses on overcoming drug resistance, a significant issue affecting over 50% of cancer patients. Its lead product, ENB-001, is a first-in-class selective endothelin B receptor (ETBR) inhibitor that has demonstrated the ability to significantly reduce tumor growth and enhance survival in preclinical studies. ENB-001 works by restoring T-cell infiltration into tumors, inhibiting metastasis, and improving the efficacy of immunotherapy. The product has received Orphan Drug Designation from the FDA, granting it market exclusivity and a robust intellectual property position. ENB Therapeutics is also developing a companion diagnostic to identify patients who could benefit from ENB-001, thus broadening its potential applications within the multi-billion-dollar immunotherapy market. The company's innovative approach aims to set a new standard of care by combining its therapies with existing immuno-oncology treatments to combat drug resistance and stimulate immune responses against cancer.

Bainbridge Health, Inc. is a Philadelphia-based company founded in 2016 that specializes in developing a clinical intelligence and data analytics platform aimed at enhancing medication safety in hospital settings. The company's offerings include a vendor-agnostic medication safety platform that streamlines data management, reducing the reliance on manual data clerking and ad-hoc reporting. Their solutions, designed for medication safety leaders and hospital safety professionals, include an infusion pump management software known as InfusionWare, which centralizes infusion data to improve patient safety and effectively manage pump information. By mitigating medication errors, Bainbridge Health's platform helps healthcare providers reduce avoidable costs and improve overall patient care.

Opsidio is a biotechnology company founded in 2012 and headquartered in Bryn Mawr, Pennsylvania. The company specializes in the development of monoclonal antibodies aimed at treating fibrotic and remodeling diseases. Its innovative approach targets a specific form of the Stem Cell Factor that triggers the release of profibrotic cytokines. This targeted treatment strategy allows for potential therapies for conditions such as idiopathic pulmonary fibrosis, chronic kidney disease, systemic sclerosis, and severe asthma, addressing significant unmet medical needs in these areas.

Oncora Medical, Inc. is a digital health company based in Philadelphia, Pennsylvania, that develops an analytics platform specifically for radiation oncology. Founded in 2014, Oncora's software integrates data from various sources, including electronic medical records and treatment planning systems, to create a comprehensive database. This platform empowers radiation oncologists to use historical data and predictive analytics to make personalized treatment recommendations for cancer patients. Additionally, Oncora enables the application of machine learning algorithms to analyze patient outcomes, facilitating improved decision-making in cancer care. The company aims to enhance the effectiveness of radiation treatments by providing advanced reporting tools that unify and streamline access to critical oncology data.

Wellsheet is a technology company that specializes in optimizing clinical information management through the use of machine learning and artificial intelligence. Its cloud-based platform integrates seamlessly with existing Electronic Health Record (EHR) systems, enabling healthcare providers to access prioritized and contextualized clinical content tailored to their workflows. By enhancing the visibility of the most relevant information, Wellsheet empowers physicians to make quicker clinical decisions, thus improving patient care and operational efficiency. The company's solutions have demonstrated significant benefits in large health systems, including a notable impact within a network of 10,000 physicians in New Jersey. Additionally, Wellsheet collaborates with major EHR vendors like Epic and Cerner to distribute its services, operating on a Software as a Service (SaaS) model for healthcare organizations.

CytoVas LLC is a life science company based in Philadelphia, Pennsylvania, that specializes in developing an innovative informatics platform called CLOUD CYTOMICS. This platform is designed to analyze flow cytometry data, providing clinicians and drug developers with actionable insights into novel cellular markers related to disease progression and individual treatment responses. CLOUD CYTOMICS automates the collection, mining, and modeling of data, facilitating the rapid identification and interpretation of cellular biomarkers. The technology is applicable across various therapeutic areas and disease states, including cardiovascular disease, type 2 diabetes, and Alzheimer's, and supports all stages of drug development. Founded in 2010 by experts in computational biology and flow cytometry, CytoVas is supported by significant investments from reputable organizations and maintains partnerships with leading entities in the field.

Genome Profiling, LLC is a bioinformatics company based in Wayne, Pennsylvania, focused on the discovery of novel epigenetic biomarkers for diagnosing, treating, and predicting chronic and life-threatening diseases. Founded in 2012, the company has developed GenPro Analytics, an innovative software platform that enhances the ability of scientists and medical professionals to predict, diagnose, and monitor disease progression with improved sensitivity, specificity, accuracy, and cost-effectiveness. Genome Profiling offers a unique epigenetic biomarker discovery platform that integrates a proprietary pre-NGS gDNA preparation kit with advanced NGS data analytics algorithms, allowing for efficient incorporation into standard NGS workflows. This technology enables a single NGS run to yield comprehensive genomic variant call analyses alongside epigenetic data, positioning Genome Profiling at the forefront of the rapidly emerging market in genomic and epigenetic research.

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Wayne, Pennsylvania, established in 2015. The company specializes in developing and commercializing targeted therapies for serious and rare genetic skin diseases, focusing on addressing the root causes of these conditions. Its lead product candidate, QTORIN, is an anhydrous gel formulated to ensure drug stability at room temperature while enabling effective distribution into skin layers where various dermatologic pathologies occur. Palvella Therapeutics is committed to serving patient populations that have been overlooked, with an initial emphasis on conditions such as microcystic lymphatic malformations and cutaneous venous malformations, leveraging its patented QTORIN platform to advance its therapeutic pipeline.

WellTrackONE, LLC is a population health management company based in Hilton Head Island, South Carolina, with an additional location in New York, New York. Established in 2010, the company provides wellness programs designed for healthcare providers and organizations across the United States. Its services include managing annual wellness visits for Medicare patients, supplying critical data for accountable care organizations, and assisting healthcare systems in meeting clinical indicators and quality measures. WellTrackONE also offers customized wellness solutions for commercial organizations and delivers clinical risk management services that generate comprehensive baseline reports detailing modifiable risk factors and preventative goals. By streamlining scheduling, screening, and documentation processes, WellTrackONE enables healthcare professionals to enhance patient care and improve revenue generation while ensuring compliance with healthcare standards.

Olive Devices LLC is an assistive device company based in Philadelphia, Pennsylvania, that specializes in designing and developing smart glasses aimed at enhancing communication for individuals who are deaf or hard of hearing, as well as those with attention deficit disorders and early onset Alzheimer’s. The smart glasses feature real-time speech-to-text captions that appear in front of the user's eyes, facilitating better understanding and engagement. In addition to the glasses, Olive Devices offers a mobile application that supports personalized education by syncing captions to the cloud, allowing users to organize and select relevant information for note-taking and studying. The application also includes features that transform notes into memory games and study tools, as well as facilitate communication with teachers. Founded in 2015, Olive Devices provides its innovative solutions to a diverse range of users, including teachers, students, parents, audiologists, and optometrists.

TalexMedical, LLC is a medical device company based in Philadelphia, Pennsylvania, that specializes in developing and manufacturing innovative solutions for treating external ear deformities in newborns. The company's flagship product, Infantear, is a Class I medical device designed as a nonsurgical ear molding system that can be applied in an outpatient setting, effectively replacing traditional surgical procedures. Infantear is customizable and constructed from soft materials, ensuring comfort for infants. This device allows pediatricians to address ear anomalies with a straightforward two-week treatment during the critical first three weeks of life, thereby reducing the need for costly and time-consuming referrals to specialists. Established in 2015, TalexMedical focuses on improving healthcare outcomes while enhancing patient satisfaction and minimizing costs.

HueDx is a company focused on the development and launch of rapid, quantitative, assay-based tests designed to enhance patient care. Utilizing innovative paper- or wax-based microfluidics technology, HueDx creates point-of-care diagnostic tests that deliver fast results across a range of applications. This approach not only reduces the costs associated with traditional diagnostic methods but also increases transparency and accessibility for clinicians. By eliminating the need to develop physical devices and software, HueDx streamlines the process of bringing RQA products to market, ultimately improving the patient care cycle.

Venatorx Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the discovery and development of innovative anti-infective agents aimed at addressing multi-drug-resistant (MDR) bacterial infections and challenging viral infections. Founded in 2010 and headquartered in Malvern, Pennsylvania, the company specializes in creating antibacterial drugs that target resistant pathogens, including those responsible for difficult-to-treat infections such as MRSA, Pseudomonas, and Salmonella. By employing novel chemical approaches, Venatorx develops treatments with selective and potent activity against various bacterial resistance mechanisms, thereby enhancing the therapeutic options available to healthcare professionals and addressing significant unmet medical needs in the field of infectious diseases.

Ride Health LLC is a healthcare technology company that provides a software-as-a-service platform designed to facilitate patient transportation to medical appointments. Founded in 2016 and headquartered in New York, the company collaborates with healthcare organizations and transportation providers to streamline the management of transportation benefits. Its platform allows healthcare coordinators to schedule rides for patients in advance or on-demand, while also offering real-time insights into transportation costs and usage. By integrating technology with a human-centered approach, Ride Health addresses transportation barriers faced by at-risk populations, ensuring that patients receive the necessary care. The platform personalizes the ride experience by mapping out each patient's unique needs, ultimately leading to improved access to care, greater efficiencies, reduced costs, and better health outcomes.

Pillo Health is a company focused on enhancing the quality of life for patients managing their health at home through its innovative care delivery platform. Central to this platform is Pillo, an intelligent healthcare assistant designed to assist caregivers and health organizations in delivering improved care. Pillo manages medication schedules, provides personalized health and wellness information, and proactively delivers digital care plans to patients. Additionally, it facilitates communication between patients and care teams through smart notifications and video calling. Pillo Health also offers a software development kit (SDK) that allows partner organizations to create customized skills for the Pillo device, further expanding its capabilities in home healthcare management.

Keriton LLC is a company that specializes in providing a pumped breast milk management system tailored for neonatal intensive care units (NICUs). Its platform facilitates the tracking of milk-bottle inventory, feeding orders, and recipes through mobile devices. The system enhances patient safety by implementing first-in-first-out (FIFO) bottle flow management, notifying users of expiry dates, and issuing alerts for potential misfeeds. Additionally, Keriton offers a media-sharing platform that allows nurses to share photos and videos of NICU babies with their mothers, fostering communication and engagement. The company also provides real-time insights into the milk production patterns of lactating mothers. Incorporated in 2016 and based in Philadelphia, Pennsylvania, Keriton's software-as-a-service (SaaS) solution has been deployed in various large healthcare systems, managing over 1.5 million feeds and significantly reducing nursing errors while improving overall patient outcomes.

Mebias Discovery, LLC is a pharmaceutical company focused on the discovery and development of pathway-selective drugs targeting G-protein coupled receptors (GPCRs). Founded in 2015 and headquartered in Philadelphia, Pennsylvania, the company aims to identify innovative molecules that bind to GPCRs, thereby minimizing on-target side effects traditionally associated with drug therapies. Mebias Discovery's technology emphasizes validated drug discovery methods, offering a robust platform that reduces the risks typically associated with exploring new therapeutic mechanisms. The company's research primarily targets neurodegenerative disorders, mood disorders, non-opioid pain management, cardiovascular conditions, and immuno-oncology, presenting significant opportunities for healthcare providers to address various diseases with improved therapeutic profiles.

Cohero Health, Inc. is a digital respiratory health company that focuses on developing solutions for the management of asthma and chronic obstructive pulmonary disease. The firm offers a connected health platform that includes the BreatheSmart app, which provides personalized reminders for medication adherence, tracks inhaler usage, measures lung function, and monitors symptoms and environmental conditions. Cohero Health also supplies mSpirometer lung function sensors and HeroTracker, a Bluetooth-enabled inhaler tracker for both control and rescue medications. Additionally, the company offers BreatheSmart Connect, a Software-as-a-Service solution that facilitates remote monitoring and communication between patients and healthcare providers. Founded in 2012 and headquartered in New York, Cohero Health operates as a subsidiary of AptarGroup, Inc.

Genome Profiling, LLC is a bioinformatics company based in Wayne, Pennsylvania, focused on the discovery of novel epigenetic biomarkers for diagnosing, treating, and predicting chronic and life-threatening diseases. Founded in 2012, the company has developed GenPro Analytics, an innovative software platform that enhances the ability of scientists and medical professionals to predict, diagnose, and monitor disease progression with improved sensitivity, specificity, accuracy, and cost-effectiveness. Genome Profiling offers a unique epigenetic biomarker discovery platform that integrates a proprietary pre-NGS gDNA preparation kit with advanced NGS data analytics algorithms, allowing for efficient incorporation into standard NGS workflows. This technology enables a single NGS run to yield comprehensive genomic variant call analyses alongside epigenetic data, positioning Genome Profiling at the forefront of the rapidly emerging market in genomic and epigenetic research.

Immunome Inc., founded in 2006 and headquartered in Exton, Pennsylvania, is a biotechnology company focused on discovering, developing, and commercializing highly targeted and native human cancer antibodies against universal cancer antigens. The company utilizes its proprietary RealMAb technology to identify novel antigens and the corresponding native human antibodies that target them. Additionally, Immunome employs ScreenMab multiplex functional screening technology to pinpoint monoclonal antibodies with high specificity for tumor neoantigens.

Mebias Discovery, LLC is a pharmaceutical company focused on the discovery and development of pathway-selective drugs targeting G-protein coupled receptors (GPCRs). Founded in 2015 and headquartered in Philadelphia, Pennsylvania, the company aims to identify innovative molecules that bind to GPCRs, thereby minimizing on-target side effects traditionally associated with drug therapies. Mebias Discovery's technology emphasizes validated drug discovery methods, offering a robust platform that reduces the risks typically associated with exploring new therapeutic mechanisms. The company's research primarily targets neurodegenerative disorders, mood disorders, non-opioid pain management, cardiovascular conditions, and immuno-oncology, presenting significant opportunities for healthcare providers to address various diseases with improved therapeutic profiles.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, specializing in the development of small molecule drugs and therapeutics aimed at treating various chronic diseases. Founded in 2004, the company focuses on creating peripherally selective agents across multiple therapeutic areas, including diabetes, nonalcoholic fatty liver disease (NAFLD/NASH), obesity, autoimmune and inflammatory disorders, as well as malaria. By targeting peripheral tissues, Jenrin Discovery aims to enhance treatment options for physicians and improve patient outcomes in these significant health areas.

Bainbridge Health, Inc. is a Philadelphia-based company founded in 2016 that specializes in developing a clinical intelligence and data analytics platform aimed at enhancing medication safety in hospital settings. The company's offerings include a vendor-agnostic medication safety platform that streamlines data management, reducing the reliance on manual data clerking and ad-hoc reporting. Their solutions, designed for medication safety leaders and hospital safety professionals, include an infusion pump management software known as InfusionWare, which centralizes infusion data to improve patient safety and effectively manage pump information. By mitigating medication errors, Bainbridge Health's platform helps healthcare providers reduce avoidable costs and improve overall patient care.

Enzium, Inc. specializes in the development and marketing of fluorescence-based reagents for the detection of protease activity. Founded in 2011 and based in Pittsburgh, Pennsylvania, the company offers a range of protease activity sensors utilized in the diagnostic and life science industries, including assays for caspases, matrix metalloproteinases, and microbial proteases. Enzium's proprietary modular technology allows for the rapid customization of assay reagents by swapping protein modules, akin to building with Legos. This innovative approach enables their customers, spanning pharmaceutical, biotech, contract research organizations, academia, and government sectors, to seamlessly integrate their reagents into various applications throughout research, drug development, and diagnostic pipelines.

Olive Devices LLC is an assistive device company based in Philadelphia, Pennsylvania, that specializes in designing and developing smart glasses aimed at enhancing communication for individuals who are deaf or hard of hearing, as well as those with attention deficit disorders and early onset Alzheimer’s. The smart glasses feature real-time speech-to-text captions that appear in front of the user's eyes, facilitating better understanding and engagement. In addition to the glasses, Olive Devices offers a mobile application that supports personalized education by syncing captions to the cloud, allowing users to organize and select relevant information for note-taking and studying. The application also includes features that transform notes into memory games and study tools, as well as facilitate communication with teachers. Founded in 2015, Olive Devices provides its innovative solutions to a diverse range of users, including teachers, students, parents, audiologists, and optometrists.

Penn State Health is a multi-hospital health system based in Central Pennsylvania, distinguished as the region's only academic medical center. It operates the Milton S. Hershey Medical Center, a 551-bed Level I regional trauma center, which includes the Children's Hospital and is affiliated with the Penn State College of Medicine. The system is recognized for its capability to handle complex adult and pediatric cases, reflecting its commitment to high-quality patient care. Additionally, Penn State Health has achieved ANCC Magnet Recognition, underscoring its dedication to fostering a professional environment that promotes staff development and enhances the overall patient experience.

Cohero Health, Inc. is a digital respiratory health company that focuses on developing solutions for the management of asthma and chronic obstructive pulmonary disease. The firm offers a connected health platform that includes the BreatheSmart app, which provides personalized reminders for medication adherence, tracks inhaler usage, measures lung function, and monitors symptoms and environmental conditions. Cohero Health also supplies mSpirometer lung function sensors and HeroTracker, a Bluetooth-enabled inhaler tracker for both control and rescue medications. Additionally, the company offers BreatheSmart Connect, a Software-as-a-Service solution that facilitates remote monitoring and communication between patients and healthcare providers. Founded in 2012 and headquartered in New York, Cohero Health operates as a subsidiary of AptarGroup, Inc.

Noble.MD is a healthcare technology company based in Bryn Mawr, Pennsylvania, founded in 2012. It develops Theo, a digital healthcare advisory platform designed to identify health and behavioral risks for patients. The platform enables patients to actively manage these risks through tailored programs and interventions. By capturing essential patient data at the point of care, Noble.MD facilitates value-based reimbursement and aligns the interests of providers and payers, enhancing the processes of risk identification, coding, and management. Through its innovative approach, Noble.MD engages patients in understanding their symptoms, behaviors, and intentions, while encouraging actionable steps towards improved health outcomes.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, specializing in the development of small molecule drugs and therapeutics aimed at treating various chronic diseases. Founded in 2004, the company focuses on creating peripherally selective agents across multiple therapeutic areas, including diabetes, nonalcoholic fatty liver disease (NAFLD/NASH), obesity, autoimmune and inflammatory disorders, as well as malaria. By targeting peripheral tissues, Jenrin Discovery aims to enhance treatment options for physicians and improve patient outcomes in these significant health areas.

Oncora Medical, Inc. is a digital health company based in Philadelphia, Pennsylvania, that develops an analytics platform specifically for radiation oncology. Founded in 2014, Oncora's software integrates data from various sources, including electronic medical records and treatment planning systems, to create a comprehensive database. This platform empowers radiation oncologists to use historical data and predictive analytics to make personalized treatment recommendations for cancer patients. Additionally, Oncora enables the application of machine learning algorithms to analyze patient outcomes, facilitating improved decision-making in cancer care. The company aims to enhance the effectiveness of radiation treatments by providing advanced reporting tools that unify and streamline access to critical oncology data.

Mebias Discovery, LLC is a pharmaceutical company focused on the discovery and development of pathway-selective drugs targeting G-protein coupled receptors (GPCRs). Founded in 2015 and headquartered in Philadelphia, Pennsylvania, the company aims to identify innovative molecules that bind to GPCRs, thereby minimizing on-target side effects traditionally associated with drug therapies. Mebias Discovery's technology emphasizes validated drug discovery methods, offering a robust platform that reduces the risks typically associated with exploring new therapeutic mechanisms. The company's research primarily targets neurodegenerative disorders, mood disorders, non-opioid pain management, cardiovascular conditions, and immuno-oncology, presenting significant opportunities for healthcare providers to address various diseases with improved therapeutic profiles.

Enzium, Inc. specializes in the development and marketing of fluorescence-based reagents for the detection of protease activity. Founded in 2011 and based in Pittsburgh, Pennsylvania, the company offers a range of protease activity sensors utilized in the diagnostic and life science industries, including assays for caspases, matrix metalloproteinases, and microbial proteases. Enzium's proprietary modular technology allows for the rapid customization of assay reagents by swapping protein modules, akin to building with Legos. This innovative approach enables their customers, spanning pharmaceutical, biotech, contract research organizations, academia, and government sectors, to seamlessly integrate their reagents into various applications throughout research, drug development, and diagnostic pipelines.

RiboNova Inc. is a biopharmaceutical company based in Wynnewood, Pennsylvania, specializing in the development of small molecule drugs aimed at treating serious rare diseases, including mitochondrial disorders and certain types of cancer. Founded in 2011, RiboNova focuses on innovative therapies that target defective transfer RNAs and ribonucleic acid anomalies. The company's drug discovery platform is designed to create precision medicines that provide healthcare professionals with effective treatment options for patients suffering from these conditions. RiboNova operates within the Lankenau Institute for Medical Research, leveraging its research capabilities to advance its therapeutic pipeline.

Cohero Health, Inc. is a digital respiratory health company that focuses on developing solutions for the management of asthma and chronic obstructive pulmonary disease. The firm offers a connected health platform that includes the BreatheSmart app, which provides personalized reminders for medication adherence, tracks inhaler usage, measures lung function, and monitors symptoms and environmental conditions. Cohero Health also supplies mSpirometer lung function sensors and HeroTracker, a Bluetooth-enabled inhaler tracker for both control and rescue medications. Additionally, the company offers BreatheSmart Connect, a Software-as-a-Service solution that facilitates remote monitoring and communication between patients and healthcare providers. Founded in 2012 and headquartered in New York, Cohero Health operates as a subsidiary of AptarGroup, Inc.

Hsiri Therapeutics, LLC is a pharmaceutical company focused on the discovery and development of innovative antibiotics to address serious infectious diseases caused by drug-resistant bacteria. Founded in 2012 and based in Media, Pennsylvania, the company primarily targets mycobacterial diseases and gram-negative infections. Its product pipeline includes HT-01, a topical treatment for gram-positive infections; HT-02, designed for serious gram-positive infections; HT-03, an anti-mycobacterial agent for mycobacterium avium-intracellulare complex; HT-04, aimed at drug-resistant mycobacterium tuberculosis; and HT-05, a novel compound based on modified amino-penicillin structures. Hsiri Therapeutics also explores therapies for infections caused by acinetobacter and klebsiella. The company's research has its roots in the laboratories of Professor Marvin Miller at the University of Notre Dame, emphasizing a commitment to developing effective solutions for difficult-to-treat bacterial infections.

Enzium, Inc. specializes in the development and marketing of fluorescence-based reagents for the detection of protease activity. Founded in 2011 and based in Pittsburgh, Pennsylvania, the company offers a range of protease activity sensors utilized in the diagnostic and life science industries, including assays for caspases, matrix metalloproteinases, and microbial proteases. Enzium's proprietary modular technology allows for the rapid customization of assay reagents by swapping protein modules, akin to building with Legos. This innovative approach enables their customers, spanning pharmaceutical, biotech, contract research organizations, academia, and government sectors, to seamlessly integrate their reagents into various applications throughout research, drug development, and diagnostic pipelines.

CarePartners Plus, LLC is a technology-enabled health care communications and data company based in Horsham, Pennsylvania. Established in 2009, it focuses on providing patient management and engagement solutions that enhance health care delivery. The company's flagship product, Wellby, is a cloud-based system designed to facilitate patient interaction and engagement, promoting a more personalized health care experience. CarePartners Plus captures and analyzes real-time patient-generated data, enabling healthcare providers, insurers, and stakeholders to improve patient experiences and outcomes. The company serves a diverse clientele, including pharmaceutical companies, hospitals, health insurers, employers, and government agencies, offering tools for caregiver management, care coordination, and cost containment.

Allevi is a pioneering company that develops innovative tools for designing and engineering 3D tissues. It specializes in desktop 3D bioprinters capable of creating functional, three-dimensional living tissues, alongside proprietary bioinks composed of collagen and hyaluronic acid. Allevi's cloud-based platform, Bioprint Online, allows users to design structures, select materials, and monitor the printing process. Its products cater to a diverse clientele, including researchers in tissue engineering, regenerative medicine, material science, and cell biology, as well as industrial and pharmaceutical companies involved in drug testing and development. Additionally, Allevi sells its bioinks online. Founded in 2014 and headquartered in Philadelphia, Pennsylvania, the company was previously known as BioBots, Inc.

WellTrackONE, LLC is a population health management company based in Hilton Head Island, South Carolina, with an additional location in New York, New York. Established in 2010, the company provides wellness programs designed for healthcare providers and organizations across the United States. Its services include managing annual wellness visits for Medicare patients, supplying critical data for accountable care organizations, and assisting healthcare systems in meeting clinical indicators and quality measures. WellTrackONE also offers customized wellness solutions for commercial organizations and delivers clinical risk management services that generate comprehensive baseline reports detailing modifiable risk factors and preventative goals. By streamlining scheduling, screening, and documentation processes, WellTrackONE enables healthcare professionals to enhance patient care and improve revenue generation while ensuring compliance with healthcare standards.

Galleon Pharmaceuticals, Inc. is a pharmaceutical company based in Horsham, Pennsylvania, focused on discovering and developing innovative treatments for sleep apnea and related breathing control disorders. Established in 2003, the company is engaged in creating a portfolio of therapeutics aimed at addressing a variety of respiratory conditions, including sleep apnea, ventilator weaning, anesthetic-induced respiratory depression, chronic obstructive pulmonary disease (COPD), and obesity-hypoventilation syndrome. Among its key offerings are GAL-021, an intravenous small molecule that supports respiratory drive in surgical and critical care patients, GLN-21,160, an oral candidate for sleep apnea, and GAL-044, which serves as a preventative medication for surgical pain. Galleon Pharmaceuticals is committed to enhancing patient care through its neuro-respiratory drug development initiatives.

Enzium, Inc. specializes in the development and marketing of fluorescence-based reagents for the detection of protease activity. Founded in 2011 and based in Pittsburgh, Pennsylvania, the company offers a range of protease activity sensors utilized in the diagnostic and life science industries, including assays for caspases, matrix metalloproteinases, and microbial proteases. Enzium's proprietary modular technology allows for the rapid customization of assay reagents by swapping protein modules, akin to building with Legos. This innovative approach enables their customers, spanning pharmaceutical, biotech, contract research organizations, academia, and government sectors, to seamlessly integrate their reagents into various applications throughout research, drug development, and diagnostic pipelines.

HealthQx, established in 2012 and headquartered in King of Prussia, Pennsylvania, specializes in Value-based Payment (VBP) analytic software solutions for health plans and providers. Its flagship product, ClarityQx, empowers users to design, implement, and monitor the performance of alternative payment models such as episodic or bundled arrangements. The platform facilitates provider engagement and contract negotiation processes, aiming to enhance consumer care while reducing medical costs.

TowerView helps the 1 in 3 Americans with a chronic illness manage multiple medications. TowerView’s patients receive pre-filled medication trays that fit into a connected pillbox like a K-Cup into a Keurig coffee machine. Their pillbox can sense when patients forget a dose and automatically sends a text or phone reminder. Unlike other smart pillboxes, they send patients pre-filled medication trays sourced from a pharmacy so patients never have to fill their own pillbox and they work directly with nurses​ to target outreach for non-adherent patients. TowerView is rolling out with Independence Blue Cross in January 2015 and are in advanced discussions with numerous other health plans.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, specializing in the development of small molecule drugs and therapeutics aimed at treating various chronic diseases. Founded in 2004, the company focuses on creating peripherally selective agents across multiple therapeutic areas, including diabetes, nonalcoholic fatty liver disease (NAFLD/NASH), obesity, autoimmune and inflammatory disorders, as well as malaria. By targeting peripheral tissues, Jenrin Discovery aims to enhance treatment options for physicians and improve patient outcomes in these significant health areas.

Merganser Biotech, Inc. is a biotechnology company focused on developing innovative medicines for rare hematological and iron overload diseases, including hemochromatosis, polycythemia vera, and beta thalassemia. Established in 2011 and headquartered in King of Prussia, Pennsylvania, the company specializes in creating hepcidin mimetic peptides aimed at regulating iron metabolism and addressing ineffective erythropoiesis. Through its research and development efforts, Merganser Biotech strives to provide effective treatments that enhance patient outcomes in the management of these complex conditions.

Hsiri Therapeutics, LLC is a pharmaceutical company focused on the discovery and development of innovative antibiotics to address serious infectious diseases caused by drug-resistant bacteria. Founded in 2012 and based in Media, Pennsylvania, the company primarily targets mycobacterial diseases and gram-negative infections. Its product pipeline includes HT-01, a topical treatment for gram-positive infections; HT-02, designed for serious gram-positive infections; HT-03, an anti-mycobacterial agent for mycobacterium avium-intracellulare complex; HT-04, aimed at drug-resistant mycobacterium tuberculosis; and HT-05, a novel compound based on modified amino-penicillin structures. Hsiri Therapeutics also explores therapies for infections caused by acinetobacter and klebsiella. The company's research has its roots in the laboratories of Professor Marvin Miller at the University of Notre Dame, emphasizing a commitment to developing effective solutions for difficult-to-treat bacterial infections.

Novira Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Doylestown, Pennsylvania, focused on the discovery and development of antiviral drugs targeting chronic hepatitis B (HBV) and human immunodeficiency virus (HIV) infections. Founded in 2006, the company specializes in creating first-in-class oral therapeutics that inhibit the viral capsid, offering innovative treatment options both as standalone therapies and in combination with existing treatments. Novira's antiviral drugs aim to address significant limitations associated with current therapies for chronic HBV and HIV, particularly the challenges of drug resistance and the need for lifelong treatment. By employing a novel mechanism of action, Novira Therapeutics seeks to provide more effective and potentially curative solutions for these global health issues. As of December 2015, Novira operates as a subsidiary of Johnson & Johnson.

Ossianix Inc. is a biotherapeutics company that specializes in developing single domain antibodies derived from the VNAR structure of sharks. Founded in 2012 and headquartered in Philadelphia, Pennsylvania, with research facilities in Stevenage, United Kingdom, Ossianix utilizes its VNAR platform to create high-affinity products that address various therapeutic targets. This innovative approach allows for the rapid development of bispecific and trispecific antibodies, which can be tailored for specific clinical applications, including targeting the blood-brain barrier and gastrointestinal tract. The company has also established a strategic research collaboration with Lundbeck A/S to advance its drug discovery programs across different therapeutic areas.

Immunome Inc., founded in 2006 and headquartered in Exton, Pennsylvania, is a biotechnology company focused on discovering, developing, and commercializing highly targeted and native human cancer antibodies against universal cancer antigens. The company utilizes its proprietary RealMAb technology to identify novel antigens and the corresponding native human antibodies that target them. Additionally, Immunome employs ScreenMab multiplex functional screening technology to pinpoint monoclonal antibodies with high specificity for tumor neoantigens.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company based in New York, focused on developing innovative treatments for central nervous system (CNS) diseases. Established in 2004, the company is primarily working on its lead product candidate, d-Methadone, which is undergoing Phase II clinical trials for conditions such as major depressive disorder and neuropathic pain. In addition to d-Methadone, Relmada is developing LevoCap ER, a sustained-release formulation of levorphanol designed to be abuse-resistant; BuTab, an oral formulation of buprenorphine; and MepiGel, a topical formulation of mepivacaine intended for localized anesthesia. The company's research aims to address significant unmet medical needs in CNS disorders and improve patient outcomes.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, specializing in the development of small molecule drugs and therapeutics aimed at treating various chronic diseases. Founded in 2004, the company focuses on creating peripherally selective agents across multiple therapeutic areas, including diabetes, nonalcoholic fatty liver disease (NAFLD/NASH), obesity, autoimmune and inflammatory disorders, as well as malaria. By targeting peripheral tissues, Jenrin Discovery aims to enhance treatment options for physicians and improve patient outcomes in these significant health areas.

Halo Labs is a life science instrumentation company based in Burlingame, California, specializing in the development of tools for biologics researchers. Formerly known as Optofluidics, the company focuses on high throughput biopharmaceutical quality control, utilizing advanced optics, image processing, and microfluidics technologies. Halo Labs' offerings include assessment of biologics-developability, formulation development, late-stage formulation, small molecule solubility, and AAV analytics. Founded in 2011, the company has gained recognition for its innovative scientific platform, which provides critical insights into the particles involved in research processes, thereby enhancing the stability and quality assessment of biological drugs.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company based in New York, focused on developing innovative treatments for central nervous system (CNS) diseases. Established in 2004, the company is primarily working on its lead product candidate, d-Methadone, which is undergoing Phase II clinical trials for conditions such as major depressive disorder and neuropathic pain. In addition to d-Methadone, Relmada is developing LevoCap ER, a sustained-release formulation of levorphanol designed to be abuse-resistant; BuTab, an oral formulation of buprenorphine; and MepiGel, a topical formulation of mepivacaine intended for localized anesthesia. The company's research aims to address significant unmet medical needs in CNS disorders and improve patient outcomes.

BioDetego is focused on advancing cancer diagnostics through its innovative platform, VASPfore, which develops a biomarker test aimed at optimizing cancer treatment protocols. This test assesses the metastatic risk in colorectal cancer patients, allowing for more informed decisions regarding chemotherapy. By accurately identifying high-risk patients who would benefit from treatment, BioDetego seeks to mitigate the unnecessary costs and adverse effects associated with treating low-risk patients. The company anticipates significant savings for payors, estimated at over $150 million annually, through reduced overall treatment expenses. BioDetego is led by David Zuzga, Ph.D., a research scientist with a background in cell and molecular biology, and Giovanni M. Pitari, M.D., Ph.D., a physician and research scientist specializing in Translational Oncology.

HealthQx, established in 2012 and headquartered in King of Prussia, Pennsylvania, specializes in Value-based Payment (VBP) analytic software solutions for health plans and providers. Its flagship product, ClarityQx, empowers users to design, implement, and monitor the performance of alternative payment models such as episodic or bundled arrangements. The platform facilitates provider engagement and contract negotiation processes, aiming to enhance consumer care while reducing medical costs.

InfraScan, Inc. is a Philadelphia-based medical device company specializing in the development and commercialization of hand-held diagnostic devices that utilize near-infrared (NIR) technology for assessing head injuries and strokes. The company’s primary product, the Infrascanner, allows clinicians to accurately detect intracranial bleeding in patients experiencing head trauma, which is critical for preventing secondary brain injuries. The device is versatile and finds applications in various settings, including hospitals, military operations, remote screenings, sports medicine, pediatrics, and ambulance services. InfraScan, founded in 2004, collaborates with distributors across North America, South America, Africa, Asia, the Middle East, and Europe to reach a wide market. The company's innovative approach was pioneered by a team of researchers and has undergone extensive clinical testing, positioning InfraScan as a leader in the realm of emergency diagnostic tools.

Merganser Biotech, Inc. is a biotechnology company focused on developing innovative medicines for rare hematological and iron overload diseases, including hemochromatosis, polycythemia vera, and beta thalassemia. Established in 2011 and headquartered in King of Prussia, Pennsylvania, the company specializes in creating hepcidin mimetic peptides aimed at regulating iron metabolism and addressing ineffective erythropoiesis. Through its research and development efforts, Merganser Biotech strives to provide effective treatments that enhance patient outcomes in the management of these complex conditions.

Venatorx Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the discovery and development of innovative anti-infective agents aimed at addressing multi-drug-resistant (MDR) bacterial infections and challenging viral infections. Founded in 2010 and headquartered in Malvern, Pennsylvania, the company specializes in creating antibacterial drugs that target resistant pathogens, including those responsible for difficult-to-treat infections such as MRSA, Pseudomonas, and Salmonella. By employing novel chemical approaches, Venatorx develops treatments with selective and potent activity against various bacterial resistance mechanisms, thereby enhancing the therapeutic options available to healthcare professionals and addressing significant unmet medical needs in the field of infectious diseases.

Immunome Inc., founded in 2006 and headquartered in Exton, Pennsylvania, is a biotechnology company focused on discovering, developing, and commercializing highly targeted and native human cancer antibodies against universal cancer antigens. The company utilizes its proprietary RealMAb technology to identify novel antigens and the corresponding native human antibodies that target them. Additionally, Immunome employs ScreenMab multiplex functional screening technology to pinpoint monoclonal antibodies with high specificity for tumor neoantigens.

Halo Labs is a life science instrumentation company based in Burlingame, California, specializing in the development of tools for biologics researchers. Formerly known as Optofluidics, the company focuses on high throughput biopharmaceutical quality control, utilizing advanced optics, image processing, and microfluidics technologies. Halo Labs' offerings include assessment of biologics-developability, formulation development, late-stage formulation, small molecule solubility, and AAV analytics. Founded in 2011, the company has gained recognition for its innovative scientific platform, which provides critical insights into the particles involved in research processes, thereby enhancing the stability and quality assessment of biological drugs.

Microbiota is spun out from university of Pennsylvania, to develop a gut microbiome-based treatment for hyperammonemia.

Annovis Bio, Inc., established in 2008 and headquartered in Berwyn, Pennsylvania, is a clinical-stage drug development company specializing in therapies for neurodegenerative disorders. Its primary focus is on Alzheimer's disease (AD) and Parkinson's disease (PD). Annovis Bio has two main compounds in clinical trials: ANVS401, currently in Phase 2a trials for early-stage AD and PD, as well as other chronic neurodegenerative conditions; and ANVS301, in Phase I trials to enhance cognitive function in advanced stages of AD. Additionally, the company is developing ANVS405 to protect the brain following traumatic brain injury or stroke.

Ossianix Inc. is a biotherapeutics company that specializes in developing single domain antibodies derived from the VNAR structure of sharks. Founded in 2012 and headquartered in Philadelphia, Pennsylvania, with research facilities in Stevenage, United Kingdom, Ossianix utilizes its VNAR platform to create high-affinity products that address various therapeutic targets. This innovative approach allows for the rapid development of bispecific and trispecific antibodies, which can be tailored for specific clinical applications, including targeting the blood-brain barrier and gastrointestinal tract. The company has also established a strategic research collaboration with Lundbeck A/S to advance its drug discovery programs across different therapeutic areas.

Enzium, Inc. specializes in the development and marketing of fluorescence-based reagents for the detection of protease activity. Founded in 2011 and based in Pittsburgh, Pennsylvania, the company offers a range of protease activity sensors utilized in the diagnostic and life science industries, including assays for caspases, matrix metalloproteinases, and microbial proteases. Enzium's proprietary modular technology allows for the rapid customization of assay reagents by swapping protein modules, akin to building with Legos. This innovative approach enables their customers, spanning pharmaceutical, biotech, contract research organizations, academia, and government sectors, to seamlessly integrate their reagents into various applications throughout research, drug development, and diagnostic pipelines.

Merganser Biotech, Inc. is a biotechnology company focused on developing innovative medicines for rare hematological and iron overload diseases, including hemochromatosis, polycythemia vera, and beta thalassemia. Established in 2011 and headquartered in King of Prussia, Pennsylvania, the company specializes in creating hepcidin mimetic peptides aimed at regulating iron metabolism and addressing ineffective erythropoiesis. Through its research and development efforts, Merganser Biotech strives to provide effective treatments that enhance patient outcomes in the management of these complex conditions.

Novira Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Doylestown, Pennsylvania, focused on the discovery and development of antiviral drugs targeting chronic hepatitis B (HBV) and human immunodeficiency virus (HIV) infections. Founded in 2006, the company specializes in creating first-in-class oral therapeutics that inhibit the viral capsid, offering innovative treatment options both as standalone therapies and in combination with existing treatments. Novira's antiviral drugs aim to address significant limitations associated with current therapies for chronic HBV and HIV, particularly the challenges of drug resistance and the need for lifelong treatment. By employing a novel mechanism of action, Novira Therapeutics seeks to provide more effective and potentially curative solutions for these global health issues. As of December 2015, Novira operates as a subsidiary of Johnson & Johnson.

Immunome Inc., founded in 2006 and headquartered in Exton, Pennsylvania, is a biotechnology company focused on discovering, developing, and commercializing highly targeted and native human cancer antibodies against universal cancer antigens. The company utilizes its proprietary RealMAb technology to identify novel antigens and the corresponding native human antibodies that target them. Additionally, Immunome employs ScreenMab multiplex functional screening technology to pinpoint monoclonal antibodies with high specificity for tumor neoantigens.

Life Mist Technologies, Inc., based in Paoli, Pennsylvania, specializes in the development and commercialization of advanced atomization technology that generates high volumes of micron-sized droplets using low-pressure gas and liquid. Founded in 2004, the company applies its innovative technology across a diverse range of industrial applications, including aircraft fire suppression, chemical processing, emission control, and decontamination. Additionally, their technology is utilized for turbine inlet cooling and the production of artificial snow. By enhancing existing processes, Life Mist Technologies aims to address various challenges faced by industries that require effective solutions for fire suppression, cooling, and pathogen control.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, specializing in the development of small molecule drugs and therapeutics aimed at treating various chronic diseases. Founded in 2004, the company focuses on creating peripherally selective agents across multiple therapeutic areas, including diabetes, nonalcoholic fatty liver disease (NAFLD/NASH), obesity, autoimmune and inflammatory disorders, as well as malaria. By targeting peripheral tissues, Jenrin Discovery aims to enhance treatment options for physicians and improve patient outcomes in these significant health areas.

Merganser Biotech, Inc. is a biotechnology company focused on developing innovative medicines for rare hematological and iron overload diseases, including hemochromatosis, polycythemia vera, and beta thalassemia. Established in 2011 and headquartered in King of Prussia, Pennsylvania, the company specializes in creating hepcidin mimetic peptides aimed at regulating iron metabolism and addressing ineffective erythropoiesis. Through its research and development efforts, Merganser Biotech strives to provide effective treatments that enhance patient outcomes in the management of these complex conditions.

Niiki Pharma is a development-focused oncology company dedicated to creating first-in-class cancer treatments aimed at novel cellular targets, accompanied by related companion diagnostics. The company is staffed by a team of experts in cancer drug development and commercialization, emphasizing quality, efficiency, and rapid progress in its programs. By concentrating on innovative therapeutic approaches, Niiki Pharma seeks to advance the treatment landscape for cancer patients.

Innovative Supply Solutions LLC is a specialty contract service organization based in Southampton, Pennsylvania, that specializes in clinical drug supply chain management. The company offers a comprehensive range of services, including planning and forecasting for active pharmaceutical ingredients and formulated products, project management, budget management, packaging design, and inventory management. Additionally, it coordinates supply chain activities such as manufacturing, packaging, labeling, and distribution, as well as providing analytical services and consultancy. Since its inception in 2010, Innovative Supply Solutions has developed proprietary software that enhances the efficiency and effectiveness of supply chain management, enabling healthcare providers to mitigate risks associated with clinical trials while achieving cost savings and precise results. The company’s tailored solutions and proven technology allow for significant accuracy in forecasting, ensuring that variances remain under 10%.

Anakim Biologics is developing efficiencies and improvements in biologics manufacturing.

Treventis Corporation is focused on the treatment and prevention of protein misfolding diseases using its proprietary, patent-pending discovery engine known as Common Conformational Morphology (CCM). This innovative platform allows the company to identify druggable active sites in misfolded protein targets through a combination of unique in silico models and extensive expertise in drug model development across various testing methodologies. Treventis's lead program concentrates on developing anti-misfolding small molecules particularly aimed at tauopathy, which is closely linked to Alzheimer’s disease. Additionally, the company is exploring applications of its technology in oncology and other neurodegenerative disorders, showcasing the versatility and potential of its approach to rational drug design. The company's objectives include discovering compounds that can effectively block amyloid toxicity and improve treatment options for Alzheimer's patients, ideally with minimized side effects.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company based in New York, focused on developing innovative treatments for central nervous system (CNS) diseases. Established in 2004, the company is primarily working on its lead product candidate, d-Methadone, which is undergoing Phase II clinical trials for conditions such as major depressive disorder and neuropathic pain. In addition to d-Methadone, Relmada is developing LevoCap ER, a sustained-release formulation of levorphanol designed to be abuse-resistant; BuTab, an oral formulation of buprenorphine; and MepiGel, a topical formulation of mepivacaine intended for localized anesthesia. The company's research aims to address significant unmet medical needs in CNS disorders and improve patient outcomes.

Innovative Supply Solutions LLC is a specialty contract service organization based in Southampton, Pennsylvania, that specializes in clinical drug supply chain management. The company offers a comprehensive range of services, including planning and forecasting for active pharmaceutical ingredients and formulated products, project management, budget management, packaging design, and inventory management. Additionally, it coordinates supply chain activities such as manufacturing, packaging, labeling, and distribution, as well as providing analytical services and consultancy. Since its inception in 2010, Innovative Supply Solutions has developed proprietary software that enhances the efficiency and effectiveness of supply chain management, enabling healthcare providers to mitigate risks associated with clinical trials while achieving cost savings and precise results. The company’s tailored solutions and proven technology allow for significant accuracy in forecasting, ensuring that variances remain under 10%.

Halo Labs is a life science instrumentation company based in Burlingame, California, specializing in the development of tools for biologics researchers. Formerly known as Optofluidics, the company focuses on high throughput biopharmaceutical quality control, utilizing advanced optics, image processing, and microfluidics technologies. Halo Labs' offerings include assessment of biologics-developability, formulation development, late-stage formulation, small molecule solubility, and AAV analytics. Founded in 2011, the company has gained recognition for its innovative scientific platform, which provides critical insights into the particles involved in research processes, thereby enhancing the stability and quality assessment of biological drugs.

Melior Discovery, Inc. is a biotechnology company based in Exton, Pennsylvania, specializing in developing an in vivo pharmacology platform aimed at identifying novel therapeutic applications for pre-clinical and development-stage drug candidates. Founded in 2005, the company utilizes its innovative theraTRACE indications discovery platform, which systematically evaluates a single compound across multiple in vivo models. This approach enables Melior to assess the potential utility of drug candidates in various therapeutic areas, including neurodegenerative diseases, inflammation, pain management, metabolic disorders, gastrointestinal issues, cardiovascular diseases, and dermatology. Melior Discovery primarily serves clients in the pharmaceutical and biopharmaceutical industries, offering rapid and cost-effective solutions for identifying new therapeutic potentials of existing drugs.

Ceptaris Therapeutics, Inc. is a privately held specialty pharmaceutical company focused on developing innovative treatments for rare cancers. The company is working on a proprietary gel formulation of mechlorethamine hydrochloride aimed at treating early-stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If successful, this investigational drug would be the first topical mechlorethamine product available to alleviate the signs and symptoms associated with this condition. In addition to its primary focus on CTCL, Ceptaris is also advancing YT-1006, an NMDA antagonist designed for treating neuropathic pain while mitigating side effects through a unique stereochemistry approach.

Imiplex LLC is a biotechnology company based in Bristol, Pennsylvania, founded in 2003. The company specializes in developing engineered protein nanostructures for various applications, including targeted therapeutics, biosensors, and functional biomaterials. Implex's technology leverages the unique properties of proteins, such as their ability to self-assemble with atomic precision and their structural diversity. This allows for the creation of a reusable system for constructing diverse nanostructures, which can be used in early disease diagnosis, including cancer, diabetes, Alzheimer's disease, and other neurodegenerative conditions.

COOL~BIO is a biotechnology company focused on developing hypothermia-activated biologics. Therapeutic hypothermia (TH) is the process of cooling the body to prevent organ damage and is widely-used in cardiac surgery, ischemic stroke, cardiac arrest, neurosurgery and traumatic brain injury. Their lead molecule is an anti-platelet agent being developed for use during cardiopulmonary bypass.

CarePartners Plus, LLC is a technology-enabled health care communications and data company based in Horsham, Pennsylvania. Established in 2009, it focuses on providing patient management and engagement solutions that enhance health care delivery. The company's flagship product, Wellby, is a cloud-based system designed to facilitate patient interaction and engagement, promoting a more personalized health care experience. CarePartners Plus captures and analyzes real-time patient-generated data, enabling healthcare providers, insurers, and stakeholders to improve patient experiences and outcomes. The company serves a diverse clientele, including pharmaceutical companies, hospitals, health insurers, employers, and government agencies, offering tools for caregiver management, care coordination, and cost containment.